Close this search box.

Deals report: BridgeBio taps Bayer as EU partner


Plus: Viatris deal extends Idorsia’s runway; AbbVie-OSE; Merck KGaA-C4

By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst

March 5, 2024 1:32 AM UTC

With amyloidosis therapy acoramidis now under regulatory review in both the U.S. and EU, BridgeBio has chosen Bayer as its local partner ahead of a planned 2025 launch in Europe.

BridgeBio Pharma Inc. (NASDAQ:BBIO) is to receive $310 million in upfront and near-term payments, as well as undisclosed sales milestones and tiered royalties beginning “in the low thirties percent,” the company said. Bayer AG (Xetra:BAYN) will receive an exclusive license to the product in Europe…